Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
MONDO:0006115An advanced phase of chronic myelogenous leukemia. It is characterized by: 1. the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).
Also known as: blast crisis, blast phase CML, blast phase chronic granulocytic leukaemia, blast phase chronic granulocytic leukemia, blast phase chronic myelocytic leukaemia, blast phase chronic myelocytic leukemia, blast phase chronic myelogenous leukaemia, blast phase chronic myelogenous leukemia
3138 clinical trials for this condition and its sub-types, 64 tagged with Blast phase chronic myelogenous leukemia, BCR-ABL1 positive itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Leukemia combo shot and pill shows promise in early trial
Disease control Not yet recruitingThis Phase 2 trial tests a combination of two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—in 60 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see if this combo can control the disease safely. Pa…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail aims to tame tough leukemias
Disease control Not yet recruitingThis study tests a combination of seven drugs (including asciminib and venetoclax) in 30 adults with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia. The first phase checks safety, and the second phase sees if the combo helps control t…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Triple-Drug cocktail targets Hard-to-Treat blood cancers
Disease control Not yet recruitingThis phase I trial is testing whether combining three drugs—pacritinib, venetoclax, and azacitidine—is safe and tolerable for people with accelerated or blast phase myeloproliferative neoplasms, aggressive blood cancers. The study enrolls about 20 adults whose disease has progres…
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Double-Pronged immune cells take aim at stubborn blood cancers
Disease control Not yet recruitingThis phase 1 trial tests an experimental therapy called 20-19 Tan BB06z CAR-T for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to treatment. The therapy involves taking a patient's own immune T cells, genetically modifying the…
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New combo therapy aims to keep leukemia away after transplant
Disease control Not yet recruitingThis phase 2 trial tests whether adding asciminib to standard tyrosine kinase inhibitors can prevent relapse in patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia or blastic phase chronic myeloid leukemia after a stem cell transplant. 45 participan…
Phase 2 • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for tough CML: milder chemo before transplant shows promise
Disease control Not yet recruitingThis phase 2 trial tests a reduced-toxicity chemotherapy regimen (thiotepa, melphalan, fludarabine) before a stem cell transplant in 40 people with blast-phase chronic myeloid leukemia (CML), an advanced and hard-to-treat stage. The goal is to see if this gentler approach can imp…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC